Venous Thromboembolism (VTE) Market Analysis-2026

1. VENOUS THROMBOEMBOLISM (VTE) MARKET ANALYSIS INDUSTRY INSIGHTS, TRENDS, OUTLOOK, AND OPPORTUNITY ANALYSIS, 2020–2027 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

2. REPORT DESCRIPTION Venous Thromboembolism (VTE) Market - Overview Venous Thromboembolism (VTE) Market - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 According to the International Society on Thrombosis and Hemostasis, Inc., venous thromboembolism (VTE) is a leading cause of death and disability worldwide. Approximately 10 million cases of venous thromboembolism occur annually. VTE refers to the formation of blood clots in vein. If the clot is in deep vein (usually leg), it is called as deep vein thrombosis, while a clot in lungs is termed as pulmonary embolism. There are around 100,000 to 300,000 VTE related deaths reported annually in the U.S. (International Society on Thrombosis and Hemostasis, Inc.). The number is much higher in Europe, which is at 544,000 deaths annually. Moreover, it is also estimated that up to 60% of VTE cases occur during or after hospitalization. This preventable health condition is usually overlooked as a major public health problem leading to deaths. Heparin has been the gold standard for treating VTE. In a recent study published (2017) in the New England Journal of Medicine, Rivaroxaban has shown to be more effective in reducing the risk of recurrent events in patients with venous thromboembolism in equipoise with continued anticoagulation medications compared to Aspirin. Devices used for treating VTE include compression stockings, and intermittent pneumatic compression devices. Browse Research Reports: https://www.coherentmarketinsights.com/ongoing-insight/venous- thromboembolism-market-188 © Coherent market Insights. All Rights Reserved

3. REPORT DESCRIPTION The APEX (Acute Medically Ill VTE Prevention with Extended Duration Betrixaban) trial reported in March 2017 that extended use of betrixaban post parenteral prophylaxis with enoxaparin lowers the VTE incidence among patients discharged from hospital. Currently, there no anticoagulants approved for extended-duration use in patients after hospital discharge and in those who are at high risk of VTE. This treatment approach could significantly benefit those patients and be a growth contributor for the global venous thromboembolism market. Global venous thromboembolism market regional overview Based on the article published by the steering committee of world Thrombosis Day in 2014, incidence rate of VTE in North America, Western Europe, Australia and southern Latin America (Argentina) was in the range of 0.75-2.69 per 1,000 individuals, which increase to 2-7 per 1,000 individuals in population aged 70 years and above. Moreover, according to its research findings, awareness about venous thromboembolism is very low globally. Furthermore, the condition is largely undocumented, except in North America and Europe. Daiichi Sankyo Company, Limited commenced a large scale clinical registry for cancer-VTE patients in Japan, in March 2017. This facility would enroll and follow up to 10,000 cancer patients for a year to achieve following objectives: The market is poised to grow with growing awareness level, increasing healthcare spending and easier accessibility for the masses. Request a Sample copy of this reports : https://www.coherentmarketinsights.com/insight/request-sample/188 © Coherent market Insights. All Rights Reserved

4. REPORT DESCRIPTION Major market players are focused on various business strategies such as gaining product approvals from regulatory authorities, in order to expand their product portfolio. For instance, in May 2019, Pfizer, Inc. received the U.S. Food and Drugs Administration approval for FRAGMIN, a dalteparin sodium to reduce recurrence of venous thromboembolism (VTE) in pediatric patients, aged 1 month and above. Key market players are focused on various growth strategies such as gaining product approvals from regulatory authorities, in order to expand their product portfolio. For instance, in June 2017, Portola Pharmaceuticals, a U.S.-based biotechnology company, received the U.S. FDA approval for Bevyxxa (betrixaban), which thromboembolism (VTE). is indicated for prophylaxis of venous Key players in the market are involved in various strategies such as research and development, in order to provide novel products in the market. For instance, in July 2019, Bayer AG and Johnson and Johnson’s JNJ subsidiary announced new results from phase III EINSTEIN-Jr study children suffering from venous thromboembolism (VTE). Major players in the global venous thromboembolism market include Pfizer Inc., Boehringer Ingelheim GmbH, Sanofi S.A., Abbott Laboratories, Dupont Pharm Co, Bristol-Myers Squibb Company, Merck & Co. Inc., Bayer AG, Upsher-Smith Laboratories, Inc., and 3M Health Care. Buy-Now this research report: https://www.coherentmarketinsights.com/insight/buy-now/188 © Coherent market Insights. All Rights Reserved

5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved